Supplement encyclopedia

Iodine

Molecular iodine I₂ is a chemical form of iodine made up of two iodine atoms.

Double-check the conclusions and read the sources before choosing a supplement.

Main conclusion

What it may offer

  • In women aged 18–50 with cyclical breast pain and fibrosis after an insufficient response to conservative measures, molecular iodine I₂ under medical supervision may reduce pain. In one study, some women reported at least a halving of pain over six cycles of use.
  • Among women assessed at month six, at least a halving of pain was reported by 5 of 13 taking 1.5 mg, 11 of 29 taking 3 mg, 15 of 29 taking 6 mg and 1 of 12 on placebo.
  • The overall clinician assessment of simultaneous improvement in pain, tenderness and nodularity found no convincing difference between groups. This analysis found no advantage of I₂ for overall relief of all three signs.

[1]

What was studied

  • All six findings come from one study of 111 women with moderate or severe cyclical breast pain and fibrosis and normal thyroid function. This is one trial of I₂, not six independent studies.
  • Under medical supervision, 1.5, 3 or 6 mg of molecular iodine I₂ daily was compared with placebo over six cycles. Pain reported by the women and simultaneous improvement in signs on examination were assessed.

[1]

Which forms were considered

  • Molecular iodine is denoted I₂; iodide and iodate are other chemical forms of iodine. Check the form when choosing a product: the I₂ trial results cannot automatically be transferred to other forms.
  • Check the product's form and intended use: topical iodine antiseptics are not intended for oral use.

[1] [2]

How to get it from food

  • Total iodine comes from seafood, seaweed, dairy products, eggs and iodized salt.
  • These values do not determine the molecular iodine I₂ content of a food and are not equivalent to the dose studied in the trial.

[1]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Patient-reported ≥50% reduction in total Lewin painBy month six, at least a halving of pain was reported by 5 of 13 assessed with I₂ 1.5 mg and 1 of 12 on placebo.At month three, 3/13 versus 1/12; at month six, 5/13 versus 1/12 with I₂ 1.5 mg and placebo, respectively.
1/4 Very lowStudy methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.
11 trialThe effect of supraphysiologic levels of iodine on patients with cyclic mastalgia ↗111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision
  1. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia ↗
Patient-reported ≥50% reduction in total Lewin painBy month six, at least a halving of pain was reported by 11 of 29 assessed with I₂ 3 mg and 1 of 12 on placebo.At month three, 9/30 versus 1/12; at month six, 11/29 versus 1/12 with I₂ 3 mg and placebo, respectively.
1/4 Very lowStudy methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.
11 trialThe effect of supraphysiologic levels of iodine on patients with cyclic mastalgia ↗111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision
  1. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia ↗
Patient-reported ≥50% reduction in total Lewin painBy month six, at least a halving of pain was reported by 15 of 29 assessed with I₂ 6 mg and 1 of 12 on placebo.At month three, 11/29 versus 1/12; at month six, 15/29 versus 1/12 with I₂ 6 mg and placebo, respectively.
1/4 Very lowStudy methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.
11 trialThe effect of supraphysiologic levels of iodine on patients with cyclic mastalgia ↗111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision
  1. The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextInformation
Intake recommendationsThe US recommended intake for adults is 150 µg iodine daily in total from food and supplements. This is a total-intake reference, not a dose of a separate I₂ supplement.
Intake recommendationsUS total iodine intake recommendations: 220 µg/day during pregnancy, 290 µg/day while breastfeeding; children aged 1–8, 90 µg/day; ages 9–13, 120 µg/day; adolescents aged 14–18, 150 µg/day. Nutrition data do not establish the safety of milligram doses of I₂.

Iodine - Health Professional Fact Sheet ↗

Forms

Molecular iodine I₂ is a distinct chemical form. Iodide and iodate also provide iodine, but trial results for these forms cannot automatically be transferred to I₂; topical antiseptics are not intended for oral use.

Guidance for each goal

Patient-reported ≥50% reduction in total Lewin pain1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowStudy methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.

By month six, at least a halving of pain was reported by 5 of 13 assessed with I₂ 1.5 mg and 1 of 12 on placebo.

Study findings. By month six, at least a halving of pain was reported by 5 of 13 assessed with I₂ 1.5 mg and 1 of 12 on placebo.

Studied regimen1.5 mg I₂ dailyOral molecular iodine I₂
Duration and population6 treatment cycles111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision

Comparison: Placebo

Patient-reported ≥50% reduction in total Lewin pain1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowStudy methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.

By month six, at least a halving of pain was reported by 11 of 29 assessed with I₂ 3 mg and 1 of 12 on placebo.

Study findings. By month six, at least a halving of pain was reported by 11 of 29 assessed with I₂ 3 mg and 1 of 12 on placebo.

Studied regimen3 mg I₂ dailyOral molecular iodine I₂
Duration and population6 treatment cycles111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision

Comparison: Placebo

Patient-reported ≥50% reduction in total Lewin pain1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowStudy methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.

By month six, at least a halving of pain was reported by 15 of 29 assessed with I₂ 6 mg and 1 of 12 on placebo.

Study findings. By month six, at least a halving of pain was reported by 15 of 29 assessed with I₂ 6 mg and 1 of 12 on placebo.

Studied regimen6 mg I₂ dailyOral molecular iodine I₂
Duration and population6 treatment cycles111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision

Comparison: Placebo

Mean percentage change in total Lewin pain1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowStudy methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.

With I₂ 6 mg, mean pain fell by 45.4% by month three and 45.0% by month six; on placebo it rose by 20% and 8%, respectively.

Study findings. With I₂ 6 mg, mean pain fell by 45.4% by month three and 45.0% by month six; on placebo it rose by 20% and 8%, respectively.

Studied regimen1.5, 3 or 6 mg I₂ dailyOral molecular iodine I₂
Duration and population6 treatment cycles111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision

Comparison: Placebo

≥15-point reduction in Lewin pain1/4 Very lowRead moreCollapse
Confidence
1/4 Very lowStudy methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.

A reduction in pain of at least 15 points was recorded in 2 of 13 on placebo and 5 of 14, 14 of 31 and 15 of 31 with I₂ 1.5, 3 and 6 mg, respectively.

Study findings. A reduction in pain of at least 15 points was recorded in 2 of 13 on placebo and 5 of 14, 14 of 31 and 15 of 31 with I₂ 1.5, 3 and 6 mg, respectively.

Studied regimen1.5, 3 or 6 mg I₂ dailyOral molecular iodine I₂
Duration and population6 treatment cycles111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision

Comparison: Placebo

Clinician-assessed simultaneous improvement in pain, tenderness and nodularity by month 51/4 Very lowRead moreCollapse
Confidence
1/4 Very lowStudy methods: Attrition and analysis of women with available measurements, multiple outcomes, manufacturer. Consistency of findings: No grounds for a separate downgrade. Applicability to the specified group: High I₂ doses and a clinical population limit transfer to ordinary supplements. Estimate precision: Small groups; pairwise CIs have not been established. Possible publication bias: No specific data supporting a separate downgrade.

The overall clinician assessment of everyone who received at least one dose found no convincing between-group difference; a separate assessment of a selected subgroup differed.

Study findings. The overall clinician assessment of everyone who received at least one dose found no convincing between-group difference; a separate assessment of a selected subgroup differed.

Studied regimen1.5, 3 or 6 mg I₂ dailyOral molecular iodine I₂
Duration and population6 treatment cycles111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision

Comparison: Placebo

Safety and limitations

Upper level for long-term total iodine intake in adults: US 1100 µg/day, European SCF/EFSA 600 µg/day from all sources. The trial used 1.5–6 mg I₂ daily: 1500–6000 µg even before food iodine; 1 mg = 1000 µg. Such doses exceed both upper levels and are unsuitable for self-selection; the study was medically supervised. In the six-month I₂ trial, low TSH was recorded in eight women taking I₂; in seven, it returned to normal within several months of stopping. The trial excluded thyroid disease and does not determine risk in other groups. Combining potassium iodide with some blood pressure medicines or potassium-sparing diuretics may raise blood potassium. This warning concerns the potassium salt and does not automatically apply to molecular iodine I₂.

Iodine - Health Professional Fact Sheet ↗ · Summary of Tolerable Upper Intake Levels for minerals ↗ · The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia ↗

Interactions

WithEffectActionSource
Antithyroid medicines, such as methimazoleHigh iodine doses together with antithyroid medicines may further reduce thyroid function and cause hypothyroidism.Discuss a molecular iodine supplement with your treating doctor before taking it.Iodine - Health Professional Fact Sheet ↗

Food sources

Total iodine comes from seafood, seaweed, dairy products, eggs and iodized salt. These values do not determine the molecular iodine I₂ content of a food and are not equivalent to the dose studied in the trial.

Studies

PublicationWhat was studiedParticipantsForm and doseResult
The effect of supraphysiologic levels of iodine on patients with cyclic mastalgia ↗Patient-reported ≥50% reduction in total Lewin pain: Patient-reported ≥50% reduction in total Lewin pain Mean percentage change in total Lewin pain: Mean percentage change in total Lewin pain ≥15-point reduction in Lewin pain: ≥15-point reduction in Lewin pain Clinician-assessed simultaneous improvement in pain, tenderness and nodularity by month 5: Clinician-assessed simultaneous improvement in pain, tenderness and nodularity by month 5Patient-reported ≥50% reduction in total Lewin pain: 111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision Mean percentage change in total Lewin pain: 111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision ≥15-point reduction in Lewin pain: 111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervision Clinician-assessed simultaneous improvement in pain, tenderness and nodularity by month 5: 111 women aged 18–50 with normal thyroid function, moderate or severe cyclical breast pain and fibrosis after an insufficient response to conservative measures; use under medical supervisionPatient-reported ≥50% reduction in total Lewin pain: Oral molecular iodine I₂; 1.5 mg I₂ daily; 6 treatment cycles; comparison: Placebo Patient-reported ≥50% reduction in total Lewin pain: Oral molecular iodine I₂; 3 mg I₂ daily; 6 treatment cycles; comparison: Placebo Patient-reported ≥50% reduction in total Lewin pain: Oral molecular iodine I₂; 6 mg I₂ daily; 6 treatment cycles; comparison: Placebo Mean percentage change in total Lewin pain: Oral molecular iodine I₂; 1.5, 3 or 6 mg I₂ daily; 6 treatment cycles; comparison: Placebo ≥15-point reduction in Lewin pain: Oral molecular iodine I₂; 1.5, 3 or 6 mg I₂ daily; 6 treatment cycles; comparison: Placebo Clinician-assessed simultaneous improvement in pain, tenderness and nodularity by month 5: Oral molecular iodine I₂; 1.5, 3 or 6 mg I₂ daily; 6 treatment cycles; comparison: PlaceboPatient-reported ≥50% reduction in total Lewin pain: By month six, at least a halving of pain was reported by 5 of 13 assessed with I₂ 1.5 mg and 1 of 12 on placebo. Patient-reported ≥50% reduction in total Lewin pain: By month six, at least a halving of pain was reported by 11 of 29 assessed with I₂ 3 mg and 1 of 12 on placebo. Patient-reported ≥50% reduction in total Lewin pain: By month six, at least a halving of pain was reported by 15 of 29 assessed with I₂ 6 mg and 1 of 12 on placebo. Mean percentage change in total Lewin pain: With I₂ 6 mg, mean pain fell by 45.4% by month three and 45.0% by month six; on placebo it rose by 20% and 8%, respectively. ≥15-point reduction in Lewin pain: A reduction in pain of at least 15 points was recorded in 2 of 13 on placebo and 5 of 14, 14 of 31 and 15 of 31 with I₂ 1.5, 3 and 6 mg, respectively. Clinician-assessed simultaneous improvement in pain, tenderness and nodularity by month 5: The overall clinician assessment of everyone who received at least one dose found no convincing between-group difference; a separate assessment of a selected subgroup differed.